The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes

@inproceedings{Sosenko2012TheAO,
  title={The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes},
  author={Jay M Sosenko and Jay S Skyler and Jeffrey L. Mahon and Jeffrey P. Krischer and Craig Beam and David C. Boulware and Carla J Greenbaum and Lisa E. Rafkin and Catherine C Cowie and David D. Cuthbertson and Jerry P. Palmer},
  booktitle={Diabetes care},
  year={2012}
}
OBJECTIVE We assessed the utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for identifying individuals who are highly likely to progress to type 1 diabetes (T1D) within 2 years. RESEARCH DESIGN AND METHODS The DPTRS was previously developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and was subsequently validated in the TrialNet Natural History Study (TNNHS). DPTRS components included C-peptide and glucose indexes from oral glucose tolerance testing, along with age… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Diagnosis and classi fi cation of diabetes mellitus

AN Gorsuch, KM Spencer, J Lister
  • DiabetesCare
  • 2011

Diabetes Prevention TrialType 1 Study Group . Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention TrialType 1

KC Herold, W Hagopian, JA Auger
  • 2009

Type 1Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function

MD Pescovitz, CJ Greenbaum, H KrauseSteinrauf
  • N Engl J Med
  • 2009

Diabetes Prevention TrialType 1 Study Group . A risk score for type 1 diabetes derived from autoantibodypositive participants in the Diabetes Prevention TrialType 1

JM Sosenko, JS Skyler, J Mahon
  • Diabetes Care
  • 2008

Similar Papers